In Vitro Susceptibilities of 27 Rickettsiae to 13 Antimicrobials

J. M. ROLAIN, M. MAURIN, G. VESTRIS, AND D. RAOULT*

Unité des Rickettsies, Faculté de Médecine, Université de la Méditerranée,
CNRS UPR 6 A 6020, 13385 Marseille Cedex 05, France

Received 12 November 1997/Returned for modification 10 February 1998/Accepted 19 April 1998

The MICs of 13 antibiotics (doxycycline, thiamichecolin, rifampin, amoxicillin, gentamicin, co-trimoxazole, ciprofloxacin, pefloxacin, ofloxacin, erythromycin, josamycin, clarithromycin, and pristinamycin) were determined for 27 available rickettsial species or strains. We used two in vitro cell culture methods described previously: the plaque assay and the microplate colorimetric assay. Our results confirm the susceptibilities of rickettsiae to doxycycline, thiamichecolin, and florquinoinoles. Beta-lactams, aminoglycosides, and co-trimoxazole were not active. Typhus group rickettsiae were susceptible to all macrolides tested, whereas the spotted fever group rickettsiae, R. bellii, and R. canadensis were more resistant, with josamycin, a safe alternative for the treatment of Mediterranean spotted fever, being the most effective compound. Strain Bar 29, R. massiliae, R. montana, R. aeschlimannii, and R. rhipecephali, which are members of the same phylogenetic subgroup, were more resistant to rifampin than the other rickettsiae tested. Heterogeneity in susceptibility to rifampin, which we report for the first time, may explain in vivo discrepancies in the effectiveness of this antibiotic for the treatment of rickettsial diseases. We hypothesize that rifampin resistance and erythromycin susceptibility may reflect a divergence during the evolution of rickettsiae.

All members of the genus Rickettsia are obligate gram-negative intracellular bacteria. The genus comprises typhus group rickettsiae which includes R. prowazekii, the agent of epidemic typhus, and R. typhi, the agent of murine typhus; R. tsutsugamushi, reclassified as Orientia tsutsugamushi (41), the agent of scrub typhus; and spotted fever group (SFG) rickettsiae. For three species, classification remains to be firmly established: R. canadensis and R. bellii, which were previously classified in the typhus and SFG rickettsiae, respectively, and which may represent new groups (35); and R. felis, the agent of pseudotyphus described in 1994 in California (38).

The number of recognized SFG rickettsioses has recently increased. The six SFG rickettsioses previously described are Rocky Mountain spotted fever caused by R. rickettsii, Mediterranean spotted fever caused by R. conorii, Siberian tick typhus caused by R. sibirica, Israeli spotted fever caused by R. conorii serotype Israeli. Queensland tick typhus caused by R. australis, and Rickettsia sispalox caused by R. akari. Since 1984, six new SFG rickettsioses were described: the Japanese spotted fever caused by R. japonica described in 1984 (43), Flanders Island spotted fever caused by R. honei described in 1991 (40), Asthakran fever caused by R. conorii serotype asthakran reported in 1991 (41), African tick-bite fever caused by R. africanae described in 1992 (17), a new spotted fever due to “Rickettsia mongolotimonae” reported in 1996 (31, 48) in France, and very recently, R. slovaca isolated in our laboratory from a tick from a patient (32). Other SFG rickettsioses isolated from arthropods include R. rhipecephali, R. montana, R. parkeri, and Thai tick typhus and more recently, R. massiliae isolated in the Mediterranean area (2), R. helvetica isolated in Switzerland (1), strain Bar 29 isolated in Spain (3), and R. aesculimannii isolated in Morocco (4).

Tetracyclines remain the antibiotics of choice for the treatment of rickettsial diseases, with florquinoinoles used as alternative drugs (29). Adverse effects from both tetracyclines and florquinoinoles limit their use, and these antibiotics are contraindicated in pregnant women and young children. Chloramphenicol, which has been proposed as an alternative, is poorly effective in vitro and may induce bone marrow aplasia. Josamycin has been used successfully to treat pregnant women and children suffering from Mediterranean spotted fever (5). There is a need for reliable therapeutic alternatives to tetracyclines for other rickettsial diseases and for drugs that can be administered to children and pregnant women. Reports of the in vitro susceptibilities of the rickettsiae are limited, and only a few species (mainly R. conorii and R. rickettsii) have been extensively studied (3, 20). Here we report the first extensive study evaluating the in vitro susceptibilities of almost all known rickettsial species and describe the heterogeneity of the antibiotic susceptibilities among the rickettsiae.

MATERIALS AND METHODS

Antibiotic preparation. Stock solutions of the 13 antibiotics to be tested were prepared and stored at 20°C. The antibiotics used were doxycycline (Pfizer, Neuilly, France), gentamicin (Dakota Pharm, Creteil, France), rifampin (Cas-sene, Puteaux, France), erythromycin (Abbott Laboratories, Rungis, France), co-trimoxazole (Roche, Paris, France), thiamichecolin (Sanofi Winthrop, Gent-illy, France), amoxicillin (Ieecham Laboratories, Nanterre, France), pefloxacin (Rhône Poulenc Rorer, Neuilly sur Seine, France), ofloxacin (Diamant, Puteaux, France), ciprofloxacin (Bayer Pharma, Sens, France), clarithromycin (Abbott Laboratories), josamycin (Rhône Poulenc Rorer), and pristinamycin (Rhône Poulenc Rorer). Stock solutions were prepared by solubilization of antibiotics powders in sterile distilled water; however, clarithromycin, josamycin, and pristinamycin were first dissolved in methanol before being diluted in sterile distilled water. Final antibiotic solutions were made up fresh before use by dilution of concentrated stock solutions in Eagle’s minimal essential medium (MEM) supplemented with 4% fetal calf serum and 2 mM l-glutamine.

Rickettsial strains. The rickettsial strains studied are listed in Table 1. They were grown in Vero cell monolayers cultured in MEM supplemented with 4% fetal calf serum and 2 mM l-glutamine. Cell cultures were incubated at 32°C, and the rates of infection of the Vero cells were monitored daily by Gimenez staining (9) of cell samples obtained by gentle scraping of the cell monolayers. Rickettsiae were harvested after 3 to 6 days of incubation of cell cultures, when multiplication was optimal.


* Corresponding author. Mailing address: Unité des Rickettsies, Faculté de Médecine, Université de la Méditerranée, CNRS UPR 6 A 6020 27 Boulevard Jean Moulin, 13385 Marseille Cedex 05, France. Phone: (33) 4 91 38 55 17. Fax: (33) 4 91 83 03 90. E-mail: Didier .raoult@medecine.univ-mrs.fr.
order to perform susceptibility tests by both the plaque assay and the dye uptake assay, we adapted these species to different cell cultures to obtain plaque formation. Infected Vero cells were harvested in MEM, mechanically disrupted, and centrifuged at 700 × g for 10 min, and the supernatant was pelleted by centrifugation at 7,500 rpm for 10 min (Sorvall RC-2B). The supernatant was adjusted to pH 4.2 and used to infect L929 or Vero cell monolayers cultured in MEM with 4% fetal calf serum and 2 mM L-glutamine. After 7 days of incubation, cytopathic effects occurred in this cell line.

### Antibiotic susceptibility testing

The bacteriostatic activities of 13 antibiotics were evaluated by a dye uptake assay and a plaque assay as described previously (26). During antibiotic challenges, the lack of toxic effects of each antibiotic on Vero cells was verified.

**Antibiotic susceptibility testing.** The bacteriostatic activities of 13 antibiotics were evaluated by a dye uptake assay and a plaque assay as described previously (26). During antibiotic challenges, the lack of toxic effects of each antibiotic on Vero cells was verified.

#### (i) Plaque assay

Confluent Vero cells, which were grown in MEM supplemented with 4% fetal calf serum and 2 mM L-glutamine in petri dishes, were inoculated with rickettsiae so that 2,000 PFU of rickettsiae was added to each well of the second row, 200 PFU was added to each well of the third row, and 20 PFU was added to each well of the fourth row. The first row contained only MEM and was used as an untreated control, whereas 2,000 PFU of rickettsiae was added to each well of the next eight rows for the antibiotic assays. Four serial dilutions of each antibiotic were tested. The plates were incubated for 5 to 7 days at 37°C in a 5% CO₂ incubator, then the cell culture supernatant of each well was replaced by 50 μl of neutral red dye (0.15% in saline [pH 5.5]), and the plates were incubated for 1 h at 37°C in a 5% CO₂ incubator, as described previously (26).

#### (ii) Dye uptake assay

Vero cells, grown in MEM supplemented with 4% fetal calf serum and 2 mM L-glutamine in microtiter plates, were inoculated with rickettsiae so that 2,000 PFU of rickettsiae was added to each well of the second row, 200 PFU was added to each well of the third row, and 20 PFU was added to each well of the fourth row. The first row contained only MEM and was used as an untreated control, whereas 2,000 PFU of rickettsiae was added to each well of the next eight rows for the antibiotic assays. Four serial dilutions of each antibiotic were tested. The plates were incubated for 5 to 7 days at 37°C in a 5% CO₂ incubator, then the cell culture supernatant of each well was replaced by 50 μl of neutral red dye (0.15% in saline [pH 5.5]), and the plates were incubated for 1 h at 37°C in a 5% CO₂ incubator, as described previously (26).

Dye not taken up by the cells was removed by three washes with phosphate-buffered saline (pH 6.5), and the dye absorbed by the cells was extracted by the addition of 100 μl of phosphate ethanol buffer (10% ethanol in phosphate-buffered saline adjusted to pH 4.2) per well. The optical density (OD) at 492 nm of the cell supernatant in each well was determined with a spectrophotometer. The MIC was the lowest concentration of antibiotic causing complete inhibition of plaque formation.

Experiments were carried out in duplicate to verify the results.

### RESULTS

**Plaque formation with *R. africae*, strain Bar 29, *R. aeschlimannii*, “*R. mongolotimonae*,” *R. japonica*, and *R. slovaca* in L929 and Vero cells.** Attempts to produce cytopathic effects and plaque formation with the species *R. africae*, strain Bar 29, *R. aeschlimannii*, “*R. mongolotimonae*,” *R. japonica*, and *R. slovaca* in L929 and Vero cells were successful. Plaque formation in L929 cells occurred after the first passage for *R. japonica* and after the second passage for the other strains. Plaque formation in Vero cells inoculated with L929 cell-adapted rickettsiae appeared after the second passage for *R. japonica* and strain Bar 29, and the fifth passage for “*R. mongolotimonae*,” *R. aeschlimannii*, and *R. slovaca*. Cytopathic effects were visible in Vero cells after 7 to 10 days following infection with rickettsiae.

**Plaque morphology.** The time for plaque formation and the sizes of the plaques varied among the different rickettsial species studied. In the first group, including *R. rickettsii*, *R. conorii*, *R. rickettsii*, *R. parkeri*, and *R. bellii*, plaque formation occurred within 5 days after infection, and the plaques were 2 to 3 mm in diameter. In contrast, in the second group, including *R.
TABLE 2. In vitro susceptibilities of rickettsiae to antibiotics

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>MIC range (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group 1</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>0.06–0.125</td>
</tr>
<tr>
<td>Thiamphenicol</td>
<td>0.5–2</td>
</tr>
<tr>
<td>Rifampin</td>
<td>0.06–1</td>
</tr>
<tr>
<td>Amoxicillin</td>
<td>128</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>4–8</td>
</tr>
<tr>
<td>Co-trimoxazoleb</td>
<td>&gt;8/2</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>2–8</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>1–4</td>
</tr>
<tr>
<td>Josamycin</td>
<td>0.5–1</td>
</tr>
<tr>
<td>Pristinamycin</td>
<td>1–4</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>0.5–1</td>
</tr>
<tr>
<td>Ofloxacin</td>
<td>0.5–1</td>
</tr>
<tr>
<td>Pefloxacin</td>
<td>0.5–2</td>
</tr>
</tbody>
</table>


** For co-trimoxazole, MICs are of sulfamethoxazole/trimethoprim.

Rickettsiae are gram-negative bacteria primarily associated with arthropods, which are the vectors for human infections. Since they are obligate intracellular bacteria, in vitro studies of their susceptibilities to antibiotics necessitate the use of cell culture systems. Only limited studies of the in vitro antibiotic susceptibilities of SFG rickettsiae other than *R. conorii* and *R. rickettsii* have been reported (3, 20). On the other hand, the number of SFG rickettsiae has recently increased as new species have been isolated by the shell vial centrifugation technique (19) and characterized by genomic studies (34, 35). The aim of our study was to determine the antibiotic susceptibilities of most of the rickettsial species described to date and to evaluate the variability in antibiotic susceptibilities among these organisms. Only “*R. amblyommii*, *R. felis* and the AB bacterium, which were not available to us, were excluded from our study.

Previous reports have indicated that *R. japonica* (43), *R. afer* (17), and strain Bar 29 (3) did not cause cytopathic effects on Vero cell monolayers. In our study we were able to adapt *R. afer*, strain Bar 29, *R. aeschlimanni* and “*R. mongolotimonae*, *R. japonica* and *R. slovaca* to Vero cells and to induce cytopathic effects and plaque formation. Thus, all rickettsial species studied produced plaques, although we found two typical plaque morphologies. Large plaques were obtained with *R. conorii* and *R. rickettsii* strains, as described previously (44), and also with *R. australis*, Thai tick typhus rickettsia, Astrakhan fever rickettsia, *R. honei*, *R. israeli*, *R. montana*, *R. parkeri*, and *R. bellii*. In contrast, the plaques produced by *R. canadensis*, *R. akari*, *R. sibirica*, *R. aeschlimanni*, strain Bar 29, *R. rhipicephali*, *R. slovaca*, “*R. mongolotimonae*, *R. africana*, *R. sibirica*, *R. massiliae*, and *R. helvetica* were smaller and resembled those observed with typhus group rickettsiae (44). Such discrepancies were reported previously (44), and the investigators hypothesized that the culture conditions and the nature of the host cells may influence the metabolism and pathogenicity of rickettsiae.

Although beta-lactams and aminoglycosides are not effective in the treatment of rickettsial diseases, we found that high concentrations of both gentamicin and amoxicillin caused rickettsiostatic activity. Wiseman et al. (45) have shown that both penicillin G and gentamicin at concentrations of 10 and 10 µg/ml, respectively, have significant inhibitory actions on *R. prowazeki* plaque formation, and they have shown (46) that penicillin G induces the formation of spheroplasts. Co-trimoxazole was not effective against any of the strains tested in our study, which is consistent with the results of previous experiments with *R. rickettsii* and *R. conorii* (26). Furthermore, isolation of SFG rickettsiae from ticks by use of co-trimoxazole in the culture medium to prevent overgrowth of bacterial contaminants has been reported (16), and Ruiz Beltran and Herrero Herrero (37) reported that co-trimoxazole is ineffective in the treatment of rickettsioses. Thiamphenicol was found to be less effective than its analog compound chloramphenicol (26), which has long been considered an alternative antibiotic for the treatment of patients with rickettsial diseases. The potential risk of aplastic anemia in patients treated with this drug has limited its use, however, and a relapse has been reported in a patient in Israel with Mediterranean spotted fever treated with chloramphenicol (39).

Previous experiments with *R. conorii* and *R. rickettsii* strains have shown that tetracyclines are the most effective antibiotics against these organisms (26, 28), and doxycycline remains the first-line antibiotic therapy for patients with rickettsial diseases. In our study, doxycycline was highly effective against all the strains tested. However, Yagupsy and Gross (47) described a child in Israel with an SFG rickettsiosis who was treated with a 3.5-day course of doxycycline and who subsequently suffered a relapse of the disease, which indicates that the in vivo activity of doxycycline may be only rickettsiostatic.
Our results show that fluoroquinolones are very effective against rickettsiae and confirm previous experiments with *R. rickettsii* and *R. conorii* (13, 21, 24, 26, 30). Patients suffering from Mediterranean spotted fever have been successfully treated with ciprofloxacin (10, 25, 36), ofloxacin (7), and pefloxacin (14). Fluoroquinolones may be considered a safe alternative to tetracyclines for the treatment of rickettsial diseases. However, the potential toxicity of doxycycline and fluoroquinolones contraindicate their use during pregnancy and childhood. The macrolide compounds may represent a safe alternative for this population. However, a wide variability in the susceptibilities of SFG rickettsiae to macrolides has been described previously (20, 26, 27). Our results confirm that typhus group rickettsiae are susceptible to macrolide compounds, whereas SFG rickettsiae are more resistant. Variability in the results of in vitro studies on the rickettsiostatic activities of the newer macrolide compounds clarithromycin and azithromycin against *R. conorii* and *R. rickettsii* have been reported (12, 18, 20). In our study, josamycin was the most effective macrolide against the SFG rickettsiae. Two macrolide antibiotics, erythromycin and josamycin, have been evaluated in vivo (5, 22). Studies have reported clinical failures with erythromycin against Mediterranean spotted fever (22, 23), whereas josamycin proved to be useful both in adults and in children (5). Josamycin may represent a safe alternative for the treatment of other rickettsial diseases in children and pregnant women, but clinical trials are needed.

Susceptibility to rifampin also varied, with *R. massiliae*, strain Bar 29, *R. rhipicephali*, *R. aeschlimannii*, and *R. montana* being more resistant than the other rickettsiae. These results are comparable to those of previous experiments with *R. rickettsii*, *R. conorii*, and strain Bar 29 (3, 26). Bella et al. (6) reported therapeutic failures with rifampin administration to children with Mediterranean spotted fever in Catalonia in Spain. We suggest that such therapeutic failures are due to rifampin-resistant rickettsiae, because acquired resistance to rifampin, yet to be studied in rickettsiae, has been shown to occur in *Mycobacterium tuberculosis*, *Mycobacterium leprae*, *Escherichia coli*, and *Neisseria meningitidis* with mutations in the rpoB gene encoding the beta subunit of the RNA polymerase (8, 11, 15, 42). These mutations prevent rifampin from binding to the target enzyme and thereby inhibit its activity.

It is noteworthy that all rifampin-resistant strains belonged to a single phylogenetic subgroup (Fig. 1) that we have recently described (33, 35). Rifampin resistance may then reflect a divergence during the evolution of this subgroup in the gene encoding the RNA polymerase. Likewise, we hypothesize that the high levels of susceptibility of *R. typhi* and *R. prowazekii* to macrolides compared to those of the other rickettsiae tested may reflect a divergent strategic evolution involving susceptibility to macrolide antibiotics.

In summary, our report describes the antibiotic susceptibilities of most rickettsial species to a number of antibiotics. Our results confirm the in vitro activities of doxycycline, fluoroquinolones, and josamycin, which are currently used against SFG rickettsioses. We have shown for the first time variability in susceptibility to rifampin. In vivo discrepancies in the effectiveness of rifampin for the treatment of rickettsial diseases may be due to rifampin-resistant strains, although further studies with people are needed to validate this hypothesis. The availability of a larger number of strains in the future should allow further evaluation of variability in susceptibilities to antibiotics among *Rickettsia* species.

ACKNOWLEDGMENT

We thank P. Kelly for reviewing the manuscript.

REFERENCES

1. Beati, L., O. Peter, W. Burgdorfer, A. Aeschlimann, and D. Raoult. 1993. Confirmation that *Rickettsia helvetica* sp. nov. is a distinct species of the...


